Apelin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-a antagonist therapy.

Autores de IIS La Fe

• Inmaculada Carnero Sanchez

  Autor

• Joaquín Rueda Soriano

  Autor

• Carlos Gonzalez Juanatey

  Autor

Participantes ajenos a IIS La Fe

• Genre F
• Miranda-Filloy JA
• López-Mejias R
• Ochoa R
• Blanco R
• Llorca J
• González-Gay MA

Grupos

• Hemostasia, Trombosis, Arteriosclerosis y Biología vascular

Abstract

To determine whether disease activity, systemic inflammation and metabolic syndrome are potential determinants of circulating apelin in ankylosing spondylitis (AS) patients undergoing TNF-a antagonist-infliximab therapy.